{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:09:58Z","timestamp":1792271398349,"version":"4.4.0"},"reference-count":155,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ctrv.2026.103173","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:36:10Z","timestamp":1781800570000},"page":"103173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody\u2013drug conjugates"],"prefix":"10.1016","volume":"148","author":[{"given":"Hamed","family":"Wafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils C.H.","family":"van Creij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Guenther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Noeparast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Daniel","family":"Subiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Terbuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Niedersuess-Beke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Culig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Ormanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103173_bb0005","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2026.103173_bb0010","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211047352","article-title":"Metastatic urothelial Cancer: a rapidly changing treatment landscape","volume":"13","author":"Stecca","year":"2021","journal-title":"Ther Adv Med Oncol."},{"key":"10.1016\/j.ctrv.2026.103173_bb0015","doi-asserted-by":"crossref","unstructured":"Bellmunt J, Wit Rd, Vaughn DJ, Fradet Y, Lee J-L, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015\u201326.","DOI":"10.1056\/NEJMoa1613683"},{"key":"10.1016\/j.ctrv.2026.103173_bb0020","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.ctrv.2026.103173_bb0025","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of Sacituzumab Govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0030","doi-asserted-by":"crossref","unstructured":"Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, et al. Pivotal trial of Enfortumab Vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy. J Clin Oncol 2019;37:2592\u2013600.","DOI":"10.1200\/JCO.19.01140"},{"key":"10.1016\/j.ctrv.2026.103173_bb0035","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder Cancer. Cell 2017;171:540\u201356.e25."},{"key":"10.1016\/j.ctrv.2026.103173_bb0040","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1078-0432.CCR-13-1992","article-title":"A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma","volume":"20","author":"Ross","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103173_bb0045","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/annonc\/mdp488","article-title":"Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients","volume":"21","author":"La\u00e9","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0050","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103173_bb0055","doi-asserted-by":"crossref","unstructured":"Kiss B, Wyatt AW, Douglas J, Skuginna V, Mo F, Anderson S, et al. Her2 alterations in muscle-invasive bladder cancer: patient selection beyond protein expression for targeted therapy. Sci Rep 2017;7:42713.","DOI":"10.1038\/srep42713"},{"key":"10.1016\/j.ctrv.2026.103173_bb0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2014.10.009","article-title":"Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2","volume":"51","author":"Oudard","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103173_bb0065","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0070","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2026.103173_bb0075","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00428-015-1729-4","article-title":"Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer","volume":"466","author":"Tschui","year":"2015","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ctrv.2026.103173_bb0080","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41586-021-04084-z","article-title":"Structures of the HER2-HER3-NRG1\u03b2 complex reveal a dynamic dimer interface","volume":"600","author":"Diwanji","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103173_bb0085","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2026.103173_bb0090","doi-asserted-by":"crossref","unstructured":"Qu M, Zhou L, Yan X, Li S, Wu X, Xu H, et al. Advances in HER2-targeted treatment for advanced\/metastatic urothelial carcinoma. Bladder (San Franc) 2023;10:e21200012.","DOI":"10.14440\/bladder.2023.871"},{"issue":"Suppl. 4","key":"10.1016\/j.ctrv.2026.103173_bb0095","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0959-8049(01)00231-3","article-title":"EGFR and cancer prognosis","volume":"37","author":"Nicholson","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103173_bb0100","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","article-title":"Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours","volume":"60","author":"Fleischmann","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41585-025-01075-x","article-title":"HER2 and urothelial carcinoma: current understanding and future directions","volume":"23","author":"Raggi","year":"2026","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0110","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euf.2016.06.007","article-title":"Human epidermal growth factor receptor 2 overexpression in micropapillary and other variants of urothelial carcinoma","volume":"4","author":"Behzato\u011flu","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ctrv.2026.103173_bb0115","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11523-014-0341-x","article-title":"Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma","volume":"10","author":"Li","year":"2015","journal-title":"Target Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0120","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/s41379-018-0023-9","article-title":"Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility","volume":"31","author":"Moktefi","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12907-017-0046-z","article-title":"Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma","volume":"17","author":"El Ochi","year":"2017","journal-title":"BMC Clin Pathol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111547","article-title":"Evaluation of therapeutic targets in histological subtypes of bladder Cancer","volume":"22","author":"Wucherpfennig","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2026.103173_bb0135","doi-asserted-by":"crossref","unstructured":"Wang X, MacLennan GT, Zhang S, Montironi R, Lopez-Beltran A, Tan PH, et al. Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization. Hum Pathol 2009;40:211\u20137.","DOI":"10.1016\/j.humpath.2008.07.003"},{"key":"10.1016\/j.ctrv.2026.103173_bb0140","doi-asserted-by":"crossref","unstructured":"Kim B, Kim G, Song B, Lee C, Park JH, Moon KC. HER2 protein overexpression and gene amplification in plasmacytoid urothelial carcinoma of the urinary bladder. Dis Markers 2016;2016:8463731.","DOI":"10.1155\/2016\/8463731"},{"key":"10.1016\/j.ctrv.2026.103173_bb0145","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1038\/s41598-018-22126-x","article-title":"A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort","volume":"8","author":"Marzouka","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2026.103173_bb0150","doi-asserted-by":"crossref","first-page":"48905","DOI":"10.18632\/oncotarget.16554","article-title":"HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts","volume":"8","author":"Eriksson","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2026.103173_bb0155","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103173_bb0160","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00428-025-04057-x","article-title":"Clinicopathological characteristics and prognostic significance of HER2 status evaluation in patients with urothelial carcinoma: a retrospective single-center experience in China","volume":"488","author":"Yang","year":"2026","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ctrv.2026.103173_bb0165","doi-asserted-by":"crossref","unstructured":"Koshkin VS, Schafer JM, Scherrer E, Boyiddle C, Schwartz NRM, Yu H, et al. Testing and interpretation of human epidermal growth factor receptor 2 protein expression and ERBB2 gene amplification in advanced urothelial carcinoma. JCO Precis Oncol 2025;9:e2400879.","DOI":"10.1200\/PO-24-00879"},{"key":"10.1016\/j.ctrv.2026.103173_bb0170","doi-asserted-by":"crossref","unstructured":"Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB, 3rd, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 2017;35:446\u201364.","DOI":"10.1200\/JCO.2016.69.4836"},{"key":"10.1016\/j.ctrv.2026.103173_bb0175","doi-asserted-by":"crossref","unstructured":"Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. J Clin Oncol 2023;41:3867\u201372.","DOI":"10.1200\/JCO.22.02864"},{"key":"10.1016\/j.ctrv.2026.103173_bb0180","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s10620-013-2925-1","article-title":"HER2 mRNA status contributes to the discrepancy between gene amplification and protein overexpression in gastric cancer","volume":"59","author":"Ma","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ctrv.2026.103173_bb0185","first-page":"176","article-title":"HER-2 and TOP 2A gene amplifications in urinary bladder carcinoma","volume":"86","author":"Simon","year":"2002","journal-title":"Verh Dtsch Ges Pathol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0190","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1200\/JCO.2024.42.4_suppl.574","article-title":"HER2 mutation and bladder cancer (BC): prevalence and clinical outcomes","volume":"42","author":"Shah","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0195","doi-asserted-by":"crossref","first-page":"1011885","DOI":"10.3389\/fonc.2022.1011885","article-title":"HER2 expression in urothelial carcinoma, a systematic literature review","volume":"12","author":"Scherrer","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043720","article-title":"HER2 expression in bladder Cancer: a focused view on its diagnostic, prognostic, and predictive role","volume":"24","author":"Sanguedolce","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2026.103173_bb0205","doi-asserted-by":"crossref","unstructured":"Zhu K, Chang Y, Zhao D, Guo A, Cao J, Wu C, et al. Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients. Front Pharmacol 2024;Volume 15\u20132024.","DOI":"10.3389\/fphar.2024.1355081"},{"key":"10.1016\/j.ctrv.2026.103173_bb0210","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.humpath.2012.11.003","article-title":"GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas","volume":"44","author":"Cimino-Mathews","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2026.111034","article-title":"Efficacy of disitamab vedotin-based therapy in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: a systematic review and meta-analysis","volume":"44","author":"Ye","year":"2026","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.834651","article-title":"HER2 low, ultra-low, and novel complementary biomarkers: expanding the Spectrum of HER2 positivity in breast Cancer","volume":"9","author":"Venetis","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.ctrv.2026.103173_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100925","article-title":"International expert consensus recommendations for HER2 reporting in breast Cancer: focus on HER2-low and ultralow categories","volume":"39","author":"Rakha","year":"2026","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0230","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO-25-00812","volume":"43","author":"Dilawari","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0235","doi-asserted-by":"crossref","unstructured":"Lennartz M, Plage H, Hofbauer S, Furlano K, Weinberger S, Ro\u00dfner F, et al. 835 HER2 expression - ultra-low to high - is a common event and related to aggressive phenotype in urothelial bladder carcinomas. Lab Invest 2025;105:103068.","DOI":"10.1016\/j.labinv.2024.103068"},{"key":"10.1016\/j.ctrv.2026.103173_bb0240","doi-asserted-by":"crossref","first-page":"186","DOI":"10.6004\/jnccn.2026.0022","article-title":"Bladder Cancer, version 1.2026, NCCN clinical practice guidelines in oncology","volume":"24","author":"Flaig","year":"2026","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ctrv.2026.103173_bb0245","first-page":"1","article-title":"HER2 testing in multiple solid tumor types: concordance of immunohistochemistry scores between three HER2 scoring algorithms","author":"Badve","year":"2026","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ctrv.2026.103173_bb0250","doi-asserted-by":"crossref","unstructured":"Guenther M, Surendran SA, Steinke LM, Liou I, Palm MA, Heinemann V, et al. The prognostic, predictive and clinicopathological implications of KRT81\/HNF1A- and GATA6-based transcriptional subtyping in pancreatic cancer. Biomolecules 2025;15.","DOI":"10.3390\/biom15030426"},{"key":"10.1016\/j.ctrv.2026.103173_bb0255","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s10585-025-10387-6","article-title":"Breast cancer liver metastases and the impact of receptor expression on survival","volume":"43","author":"Hansson","year":"2026","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ctrv.2026.103173_bb0260","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.euo.2023.10.003","article-title":"Prognostic significance of HER2 expression in patients with Bacillus Calmette-Gu\u00e9rin-exposed non-muscle-invasive bladder Cancer","volume":"7","author":"Tan","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0265","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1016\/j.asjsur.2024.04.161","article-title":"Discordance of HER2 expression in primary and recurrent\/metastatic urothelial carcinoma in the upper tract","volume":"47","author":"Ye","year":"2024","journal-title":"Asian J Surg"},{"key":"10.1016\/j.ctrv.2026.103173_bb0270","unstructured":"Jimenez RE, Hussain M, Bianco FJ, Jr., Vaishampayan U, Tabazcka P, Sakr WA, et al. Her-2\/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001;7:2440\u20137."},{"key":"10.1016\/j.ctrv.2026.103173_bb0275","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1464-410X.2005.05452.x","article-title":"Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases","volume":"95","author":"G\u00e5rdmark","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2026.103173_bb0280","doi-asserted-by":"crossref","unstructured":"Guenther M, Brunner-V\u00e9ber A, Ormanns S. Diagnostic approaches to cancer of unknown primary\u2014the pathologist's perspective. Memo Mag Eur Med Oncol 2026;19:52\u20136.","DOI":"10.1007\/s12254-025-01093-w"},{"key":"10.1016\/j.ctrv.2026.103173_bb0285","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/2767-9764.CRC-24-0620","article-title":"Diverse ERBB2\/ERBB3 activating alterations and Coalterations have implications for HER2\/3-targeted therapies across solid tumors","volume":"5","author":"Liu","year":"2025","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.ctrv.2026.103173_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102351","article-title":"The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: a systematic review and future perspectives","volume":"104","author":"Patelli","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2026.103173_bb0295","doi-asserted-by":"crossref","unstructured":"Chen Z, Tang X, Eichholz JE, McPherson A, Thomas J, Nagar K, et al. Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer. Nat Commun 2025;17:919.","DOI":"10.1038\/s41467-025-67643-2"},{"key":"10.1016\/j.ctrv.2026.103173_bb0300","doi-asserted-by":"crossref","unstructured":"Crupi E, Cigliola A, Mercinelli C, Piacentini M, Serafin D, Maiorano BA, et al. Targeting HER2 in urothelial carcinoma: why histologic subtypes and divergent histologies matter. Clin Genitourin Cancer 2026:102583.","DOI":"10.1016\/j.clgc.2026.102583"},{"key":"10.1016\/j.ctrv.2026.103173_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100424","article-title":"Characterizing the genomic landscape of the micropapillary subtype of urothelial carcinoma of the bladder harboring activating extracellular mutations of ERBB2","volume":"37","author":"Posada","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0310","doi-asserted-by":"crossref","unstructured":"Shin JW, Kim S, Ha S, Choi B, Kim S, Im SA, et al. The HER2 S310F mutant can form an active heterodimer with the EGFR, which can be inhibited by Cetuximab but not by Trastuzumab as well as Pertuzumab. Biomolecules 2019;9.","DOI":"10.3390\/biom9100629"},{"key":"10.1016\/j.ctrv.2026.103173_bb0315","doi-asserted-by":"crossref","unstructured":"Hadadi A, Krause HB, Elliott A, Brown JT, Nazha B, Harik LR, et al. The genomic landscape of urothelial carcinoma with high and low ERBB2 expression. Cancers (Basel) 2023;15.","DOI":"10.3390\/cancers15245721"},{"key":"10.1016\/j.ctrv.2026.103173_bb0320","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/13543784.2024.2376573","article-title":"Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody-drug conjugate","volume":"33","author":"Edoardo","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ctrv.2026.103173_bb0325","unstructured":"Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget8."},{"key":"10.1016\/j.ctrv.2026.103173_bb0330","doi-asserted-by":"crossref","unstructured":"Chen Z, Tang X, Eichholz JE, McPherson A, Thomas J, Nagar K, et al. Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer. Nat Commun 2025;17:919.","DOI":"10.1038\/s41467-025-67643-2"},{"key":"10.1016\/j.ctrv.2026.103173_bb0335","doi-asserted-by":"crossref","unstructured":"Choudhury NJ, Campanile A, Antic T, Yap KL, Fitzpatrick CA, Wade JL, 3rd, et al. Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations. J Clin Oncol 2016;34:2165\u201371.","DOI":"10.1200\/JCO.2015.66.3047"},{"key":"10.1016\/j.ctrv.2026.103173_bb0340","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/cncr.28120","article-title":"Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation","volume":"119","author":"Kwak","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103173_bb0345","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41416-023-02513-6","article-title":"Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-bladder 1)","volume":"130","author":"Font","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2026.103173_bb0350","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.2015.66.3468","article-title":"Phase III, double-blind, randomized trial that compared maintenance Lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1\/2-positive metastatic bladder Cancer","volume":"35","author":"Powles","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0355","doi-asserted-by":"crossref","unstructured":"Aragon-Ching JB, Galsky MD. The role of HER2-targeted therapy in urothelial carcinomas. Expert Opin Emerg Drugs 2025:1-4.","DOI":"10.1080\/14728214.2025.2517581"},{"key":"10.1016\/j.ctrv.2026.103173_bb0360","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2026.103173_bb0365","doi-asserted-by":"crossref","unstructured":"Hussain MHA, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN, et al. Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2\/<i>neu<\/i>&#x2013;Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial. J Clin Oncol 2007;25:2218\u201324.","DOI":"10.1200\/JCO.2006.08.0994"},{"key":"10.1016\/j.ctrv.2026.103173_bb0370","doi-asserted-by":"crossref","unstructured":"Chen D, Ye Y, Guo S, Yao K. Progress in the research and targeted therapy of ErbB\/HER receptors in urothelial bladder cancer. Front Mol Biosci 2021;Volume 8\u20132021.","DOI":"10.3389\/fmolb.2021.800945"},{"key":"10.1016\/j.ctrv.2026.103173_bb0375","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000346837","article-title":"HER2 dimerization inhibitor Pertuzumab - mode of action and clinical data in breast Cancer","volume":"8","author":"Harbeck","year":"2013","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.ctrv.2026.103173_bb0380","first-page":"733","article-title":"A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK","volume":"7","author":"Dey","year":"2015","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.ctrv.2026.103173_bb0385","first-page":"355","article-title":"HER3 signaling and targeted therapy in cancer","volume":"12","author":"Mishra","year":"2018","journal-title":"Oncol Rev"},{"key":"10.1016\/j.ctrv.2026.103173_bb0390","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0395","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.22.02636","article-title":"MyPathway human epidermal growth factor receptor 2 basket study: Pertuzumab + Trastuzumab treatment of a tissue-agnostic cohort of patients with human epidermal growth factor receptor 2-altered advanced solid tumors","volume":"42","author":"Sweeney","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0400","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast Cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0405","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0410","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103173_bb0415","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","article-title":"Mechanisms of Resistance to Antibody\u2013Drug Conjugates","volume":"15","author":"Loganzo","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2026.103173_bb0420","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of Trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0425","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1200\/JCO.2026.44.7_suppl.734","article-title":"Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing bladder cancer: final results from the bladder cancer cohort in part 1 of DESTINY-PanTumor02 (DP-02)","volume":"44","author":"Jung","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0430","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","article-title":"Trastuzumab Deruxtecan with Nivolumab in HER2-expressing metastatic breast or urothelial Cancer: analysis of the phase Ib DS8201-A-U105 study","volume":"30","author":"Hamilton","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103173_bb0435","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of Disitamab Vedotin in patients with human epidermal growth factor receptor 2\u2013positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0440","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1200\/JCO.2022.40.16_suppl.4519","article-title":"A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma","volume":"40","author":"Xu","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0445","doi-asserted-by":"crossref","unstructured":"Powles T, Koshkin VS, Rosenberg JE, Matsubara N, Brown JR, Drakaki A, et al. RC48G001: a phase 2 study of disitamab vedotin in HER2-expressing previously treated advanced UC. J Clin Oncol 2026;44:LBA631-LBA.","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA631"},{"key":"10.1016\/j.ctrv.2026.103173_bb0450","doi-asserted-by":"crossref","unstructured":"Galsky MD, Koshkin VS, Campbell MT, Drakaki A, Bowman I, Rose AAN, et al. 1967MO preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la\/mUC): RC48G001 cohort C. Ann Oncol 2024;35:S1138-S9.","DOI":"10.1016\/j.annonc.2024.08.2052"},{"key":"10.1016\/j.ctrv.2026.103173_bb0455","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab Vedotin plus Toripalimab in HER2-expressing advanced urothelial Cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"New England Journal of Medicine."},{"key":"10.1016\/j.ctrv.2026.103173_bb0460","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1080\/14796694.2025.2535280","article-title":"SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma","volume":"21","author":"Powles","year":"2025","journal-title":"Future Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0465","doi-asserted-by":"crossref","first-page":"12071","DOI":"10.1002\/cam4.5893","article-title":"Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer\/cholangiocarcinoma","volume":"12","author":"de Vries","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2026.103173_bb0470","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/abt\/tbab017","article-title":"Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors","volume":"4","author":"Li","year":"2021","journal-title":"Antibody Therapeutics."},{"key":"10.1016\/j.ctrv.2026.103173_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114096","article-title":"A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma","volume":"205","author":"Qu","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103173_bb0480","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1158\/1535-7163.MCT-14-0040-T","article-title":"Preclinical profile of the HER2-targeting ADC SYD983\/SYD985: introduction of a new duocarmycin-based linker-drug platform","volume":"13","author":"Dokter","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2026.103173_bb0485","doi-asserted-by":"crossref","unstructured":"Elgersma RC, Coumans RG, Huijbregts T, Menge WM, Joosten JA, Spijker HJ, et al. Design, synthesis, and evaluation of linker-Duocarmycin payloads: toward selection of HER2-targeting antibody-drug conjugate SYD985. Mol Pharm 2015;12:1813\u201335.","DOI":"10.1021\/mp500781a"},{"key":"10.1016\/j.ctrv.2026.103173_bb0490","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1158\/1535-7163.MCT-14-0881-T","article-title":"The preclinical profile of the Duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers","volume":"14","author":"van der Lee","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2026.103173_bb0495","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0500","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1200\/JCO.2024.42.16_suppl.4568","article-title":"Preliminary efficacy and safety results from RC48-C017: a phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0505","doi-asserted-by":"crossref","unstructured":"Huang H., Ma W., Zeng X., Liu B., Dai H., Zhou G., et al. Efficacy and safety of Disitamab Vedotin combined with gemcitabine as neoadjuvant therapy in muscle-invasive bladder Cancer: An open-label, multicenter, single-arm, phase 2 trial. Eur Urol. (2025), Nov 4: S0302-2838(25)04768-2. doi: 10.1016\/j.eururo.2025.10.009. Epub ahead of print. PMID: 41193372.","DOI":"10.1016\/j.eururo.2025.10.009"},{"key":"10.1016\/j.ctrv.2026.103173_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101216","article-title":"Disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer: a proof-of-concept study","volume":"68","author":"Zhang","year":"2025","journal-title":"Neoplasia"},{"key":"10.1016\/j.ctrv.2026.103173_bb0515","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1200\/JCO.2025.43.16_suppl.4605","article-title":"Intravesical disitamab vedotin (RC48) for patients with HER2-expressing high-risk non-muscle-invasive bladder cancer: a dose-escalation phase I trial","volume":"43","author":"Chen","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0520","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ctrv.2026.103173_bb0525","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","article-title":"Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review","volume":"34","author":"Lambert","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.ctrv.2026.103173_bb0530","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0535","doi-asserted-by":"crossref","unstructured":"Eckstein M, Kl\u00fcmper N, Grivas P, Grande E, Br\u00e4gelmann J, Hoffman J, et al. 3116eP target RNA expression by tumor molecular subtypes in patients (pts) with advanced urothelial carcinoma (aUC) or muscle invasive bladder cancer (MIBC): exploratory analyses from JAVELIN bladder 100 and the tempus database. Ann Oncol 2025;36:S1508-S9.","DOI":"10.1016\/j.annonc.2025.08.3729"},{"key":"10.1016\/j.ctrv.2026.103173_bb0540","doi-asserted-by":"crossref","unstructured":"Kraevska E, Popovska S. Analysis of HER2 expression in different histological subtypes and IHC-based molecular variants of muscle-invasive bladder carcinoma. Medicina (Kaunas). 2025;61.","DOI":"10.3390\/medicina61101759"},{"key":"10.1016\/j.ctrv.2026.103173_bb0545","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.858865","article-title":"Head-to-head comparison of the expression differences of NECTIN-4, TROP-2, and HER2 in urothelial carcinoma and its histologic variants","volume":"12","author":"Fan","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0550","doi-asserted-by":"crossref","first-page":"1670574","DOI":"10.3389\/fonc.2025.1670574","article-title":"Molecular mechanisms and translational advances in bladder cancer: from driver genes to precision therapy","volume":"15","author":"Xiang","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107363","article-title":"Homodimerization of CB(2) cannabinoid receptor triggered by a bivalent ligand enhances cellular signaling","volume":"208","author":"Navarro","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ctrv.2026.103173_bb0560","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/ajcp\/aqab083","article-title":"Reappraisal of HER2 amplification in high-grade urothelial carcinoma based on 2018 ASCO\/CAP clinical practice guidelines","volume":"156","author":"Mohanty","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0565","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32110596","article-title":"Exceptional response to Trastuzumab Deruxtecan (T-DXd) in HER2-positive metastatic endometrial Cancer","volume":"32","author":"Vida","year":"2025","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0570","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody\u2013drug conjugates: fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ctrv.2026.103173_bb0575","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2026.103173_bb0580","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor activity and safety of Trastuzumab Deruxtecan in patients with HER2-low-expressing advanced breast Cancer: results from a phase Ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0585","doi-asserted-by":"crossref","unstructured":"Sledge GW, Xiu J, Mahtani RL, Sandoval Leon AC, Meric-Bernstam F, Ribeiro JR, et al. Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling. NPJ Breast Cancer 2025;12:1.","DOI":"10.1038\/s41523-025-00868-y"},{"key":"10.1016\/j.ctrv.2026.103173_bb0590","doi-asserted-by":"crossref","first-page":"1332539","DOI":"10.3389\/fphar.2023.1332539","article-title":"Advances in the study of marketed antibody-drug conjugates (ADCs) for the treatment of breast cancer","volume":"14","author":"Liang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0595","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/curroncol33020103","article-title":"Predictors of response and mechanisms of resistance to antibody drug conjugates in urothelial carcinoma","volume":"33","author":"Huang","year":"2026","journal-title":"Current Oncology"},{"key":"10.1016\/j.ctrv.2026.103173_bb0600","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1186\/s12885-025-14154-4","article-title":"RC48-ADC monotherapy or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma with HER2 low and null expression: a multicenter, real-world, retrospective study","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103173_bb0605","doi-asserted-by":"crossref","unstructured":"Li-Chung Tsao, John S. Wang, Joey Ragusa, Bushangqing Liu, Jason McBane, Ivan Spasojevic, Ping Fan, Timothy N. Trotter, Herbert Kim Lyerly, Zachary C Hartman; Abstract A059: Uncovering Bystander Killing Mechanisms of Trastuzumab Deruxtecan (T-DXd): Effective Extracellular Payload Release via Cathepsin L in HER2-low Breast Cancer.. Cancer Immunol Res. (2024); 12 (10_Supplement): A059. doi: 10.1158\/2326-6074.TUMIMM24-A059. 1 October.","DOI":"10.1158\/2326-6074.TUMIMM24-A059"},{"key":"10.1016\/j.ctrv.2026.103173_bb0610","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-Depolymerizing Agents Used in Antibody\u2013Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells","volume":"2","author":"M\u00fcller","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2026.103173_bb0615","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1124\/dmd.121.000503","article-title":"Simulating the selection of resistant cells with bystander killing and antibody Coadministration in heterogeneous human epidermal growth factor receptor 2-positive tumors","volume":"50","author":"Menezes","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ctrv.2026.103173_bb0620","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3389\/fphar.2019.00749","article-title":"Lysosomal P-gp-MDR1 confers drug resistance of Brentuximab Vedotin and its cytotoxic payload monomethyl Auristatin E in tumor cells","volume":"10","author":"Liu-Kreyche","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0625","doi-asserted-by":"crossref","unstructured":"Zou XC, Xu LY, Yuan YY, Zhang GY, Huang JB, Zeng T. Disitamab vedotin (RC48) combined with PD-1 inhibitors in locally advanced or metastatic urothelial carcinoma: clinical outcomes and prognostic factors from a multicenter real-world study. Front Immunol 2026;17:1815591.","DOI":"10.3389\/fimmu.2026.1815591"},{"key":"10.1016\/j.ctrv.2026.103173_bb0630","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts Enfortumab Vedotin response in metastatic urothelial Cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0635","doi-asserted-by":"crossref","first-page":"194","DOI":"10.6004\/jnccn.2018.7264","article-title":"Oncogenic addiction to ERBB2 signaling predicts response to Trastuzumab in urothelial Cancer","volume":"17","author":"Karass","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ctrv.2026.103173_bb0640","doi-asserted-by":"crossref","unstructured":"Osumi H, Wakatsuki T, Ooki A, Chin K, Shoji H, Ogura M, et al. Clinical relevance of circulating tumor DNA in HER2-positive advanced gastric cancer: a collaborative study of a phase Ib trial of dual HER2 and PD-1 targeted therapy (Ni-high). Ther Adv Med Oncol 2025;17:17588359251367344.","DOI":"10.1177\/17588359251367344"},{"key":"10.1016\/j.ctrv.2026.103173_bb0645","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1158\/1078-0432.CCR-24-2763","article-title":"ctDNA analysis in ERBB2-amplified colorectal Cancer: biomarker analysis of the MyPathway trial","volume":"31","author":"Meric-Bernstam","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103173_bb0650","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.breast.2022.07.010","article-title":"The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: novel prognostic indexes based on ctDNA","volume":"65","author":"Liu","year":"2022","journal-title":"The Breast"},{"key":"10.1016\/j.ctrv.2026.103173_bb0655","doi-asserted-by":"crossref","unstructured":"Bartolomucci A, Nobrega M, Ferrier T, Dickinson K, Kaorey N, Nadeau A, et al. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. Npj Precis Oncol 2025;9:84.","DOI":"10.1038\/s41698-025-00876-y"},{"key":"10.1016\/j.ctrv.2026.103173_bb0660","doi-asserted-by":"crossref","unstructured":"Wummer B, Schwartz M, Ciuro J, Ahmed S, Joshi SS, Narayan VM, et al. Overcoming resistance in advanced urothelial carcinoma: mechanisms of escape from antibody-drug conjugates and FGFR3 inhibition. Front Oncol 2025;Volume 15\u20132025.","DOI":"10.3389\/fonc.2025.1654771"},{"key":"10.1016\/j.ctrv.2026.103173_bb0665","doi-asserted-by":"crossref","DOI":"10.3390\/ph14070674","article-title":"Impact of endocytosis mechanisms for the receptors targeted by the currently approved antibody-drug conjugates (ADCs)-a necessity for future ADC research and development","volume":"14","author":"Hammood","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ctrv.2026.103173_bb0670","doi-asserted-by":"crossref","DOI":"10.3390\/cells9051260","article-title":"DHA affects microtubule dynamics through reduction of Phospho-TCTP levels and enhances the antiproliferative effect of T-DM1 in Trastuzumab-resistant HER2-positive breast cancer cell lines","volume":"9","author":"D\u2019Amico","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ctrv.2026.103173_bb0675","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010154","article-title":"Novel ADCs and strategies to overcome resistance to anti-HER2 ADCs","volume":"14","author":"D\u00edaz-Rodr\u00edguez","year":"2021","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ctrv.2026.103173_bb0680","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccell.2015.12.008","article-title":"A Biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy","volume":"29","author":"Li","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103173_bb0685","first-page":"51","article-title":"Antibody-drug conjugates in breast Cancer: a comprehensive review of how to selectively deliver payloads","volume":"16","author":"Monteiro","year":"2024","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.ctrv.2026.103173_bb0690","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2026.103173_bb0695","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/abt\/tbac001","article-title":"Novel development strategies and challenges for anti-Her2 antibody-drug conjugates","volume":"5","author":"Zhang","year":"2022","journal-title":"Antibody Therapeutics."},{"key":"10.1016\/j.ctrv.2026.103173_bb0700","doi-asserted-by":"crossref","unstructured":"Conilh L, Fournet G, Fourmaux E, Murcia A, Matera E-L, Joseph B, et al. Exatecan antibody drug conjugates based on a hydrophilic Polysarcosine drug-linker platform. Pharmaceuticals (Basel) 2021;14:247.","DOI":"10.3390\/ph14030247"},{"key":"10.1016\/j.ctrv.2026.103173_bb0705","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in HER2-low breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ctrv.2026.103173_bb0710","doi-asserted-by":"crossref","unstructured":"Ciciriello F, Pezzicoli G, Biasi A, D'Addario C, Salonne F, Porta C, et al. HER2-positive urothelial carcinoma: current evidence on targeted agents and immunotherapy-based combinations. Target Oncol 2025;20:755\u201365.","DOI":"10.1007\/s11523-025-01165-1"},{"key":"10.1016\/j.ctrv.2026.103173_bb0715","doi-asserted-by":"crossref","unstructured":"D'Amico L, Menzel U, Prummer M, M\u00fcller P, Buchi M, Kashyap A, et al. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. J Immunother Cancer 2019;7:16.","DOI":"10.1186\/s40425-018-0464-1"},{"key":"10.1016\/j.ctrv.2026.103173_bb0720","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/abt\/tbaf017","article-title":"Reprogramming the tumor microenvironment: synergistic mechanisms of antibody\u2013drug conjugates and immune checkpoint inhibitors","volume":"8","author":"Yin","year":"2025","journal-title":"Antibody Therapeutics"},{"key":"10.1016\/j.ctrv.2026.103173_bb0725","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3390\/cancers17091594","article-title":"Immune checkpoint inhibitors and antibody-drug conjugates in urothelial carcinoma: current landscape and future directions","volume":"17","author":"Yajima","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2026.103173_bb0730","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1470-2045(25)00158-5","article-title":"Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study","volume":"26","author":"Gupta","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103173_bb0735","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41746-025-01483-8","article-title":"Systematic review and meta-analysis of artificial intelligence in classifying HER2 status in breast cancer immunohistochemistry","volume":"8","author":"Albuquerque","year":"2025","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.ctrv.2026.103173_bb0740","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2026.103173_bb0745","doi-asserted-by":"crossref","unstructured":"Maloney SM, Spring CA, Morejon-Lasso LV, Prosperi JR. Mechanisms of taxane resistance. Cancers (Basel). 2020;12.","DOI":"10.3390\/cancers12113323"},{"key":"10.1016\/j.ctrv.2026.103173_bb0750","first-page":"82","article-title":"Resistance to anti-tubulin agents: from vinca alkaloids to epothilones","volume":"2","author":"Krause","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.ctrv.2026.103173_bb0755","doi-asserted-by":"crossref","first-page":"1002307","DOI":"10.37349\/etat.2025.1002307","article-title":"Strategies to overcome resistance to enfortumab vedotin and pembrolizumab for patients with urothelial carcinoma: harnessing present knowledge for future advances","volume":"6","author":"Jang","year":"2025","journal-title":"Explor Target Antitumor Ther"},{"key":"10.1016\/j.ctrv.2026.103173_bb0760","first-page":"1132","article-title":"Advances in antibody-drug conjugates for urothelial carcinoma treatment","volume":"22","author":"Wei","year":"2025","journal-title":"Cancer Biol Med"},{"issue":"13","key":"10.1016\/j.ctrv.2026.103173_bb0765","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative Enfortumab Vedotin and Pembrolizumab in bladder Cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103173_bb0770","doi-asserted-by":"crossref","unstructured":"Powles T, Rosenberg JE, Gupta S, Loriot Y, Grimm M-O, Strauss J, et al. IZABRIGHT-Bladder01: a randomized, open-label, phase 2\/3 trial of izalontamab brengitecan (iza-bren; BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), vs platinum-based chemotherapy (PBC) for patients (pts) with advanced urothelial cancer (aUC) and disease progression on or after immunotherapy. J Clin Oncol 2026;44:TPS883-TPS.","DOI":"10.1200\/JCO.2026.44.7_suppl.TPS883"},{"key":"10.1016\/j.ctrv.2026.103173_bb0775","doi-asserted-by":"crossref","unstructured":"Su Y, Chen R, Liu R, Chen J, Zhu S. Selective bladder preservation after neoadjuvant zanidatamab combined with tislelizumab and chemotherapy in patients with HER2-positive muscle-invasive bladder cancer (HARBOR): a multicenter study. J Clin Oncol 2026;44:TPS887-TPS.","DOI":"10.1200\/JCO.2026.44.7_suppl.TPS887"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:44:38Z","timestamp":1784040278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":155,"alternative-id":["S0305737226000873"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103173","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody\u2013drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103173"}}